BIOCYTOGEN Aktie

 

Under the agreement, Biocytogen's fully human antibody discovery platform will be combined with Sihuan Pharmaceutical's capabilities in drug development, manufacturing, and commercialisation. The collaboration will focus on advanced The post Biocytogen and Sihuan partner to advance new therapeutics for weight loss appeared first on Pharmaceutical Business review....

BIOCYTOGEN-B (02315.HK) announced that its partner, NEOK Bio, Inc., has recently received approval from the United States Food and Drug Administration for the investigational new drug clinical trial application of NEOK002. NEOK002 is an antibody-drug conjugate ("ADC") targeting EGFR/MUC1, intended for the treatment of solid tumo......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

On the eve of the Christmas holiday, the HSI inched up 44 points or 0.17% to close at 25,818 in the half-day session today (24th). The HSCEI added 1 point to close at 8,915. The HSTECH gained 10 points or 0.19% to close at 5,499. Market turnover amounted to $92.524 billion.The US extended the deadline for imposing additional tar......

BIOCYTOGEN-B (02315.HK) leapfrogged 22.79% at HKD35.24. The trading volume was 9.837 million shares, involving HKD327 million.The Shenzhen and Shanghai Stock Exchanges announced that BIOCYTOGEN-B was added to the list of securities eligible for the Southbound Stock Connect, effective today (24th). ~AASTOCKS Financial NewsWebsite......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

BEIJING & SHANGHAI & HONGKONG--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. („Biocytogen”, SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das innovative Arzneimittelforschung vorantreibt, gab heute seine erfolgreiche Notierung an der Shanghai Stock Exchange STAR Market bekannt. Dies folgt auf die Notierung des Unternehmens an der Hong Kong Stock Exchange im September 2022 und markiert einen bedeutenden Meilenstein bei der Etablierung von Biocytogen als erstes „H+A”-dual-notiertes globales innovatives Arzneimittelunternehmen , wodurch seine Mission gestärkt wird, zum globalen Vorreiter für neue Arzneimittel zu werden. Der IPO-Preis des Unternehmens wurde auf 26,68 RMB pro Aktie festgelegt, wobei der Eröffnungskurs bei 58 RMB lag, was einer Steigerung von 117 % gegenüber dem Ausgabepreis entspricht. Basierend auf dem Eröffnungskurs übersteigt die Marktkapitalisierung von Biocytogen 25,9 Milliarden RMB. Die propietären RenMice®-Plattformen (RenMab™, Re...

BEIJING & SHANGHAI & HONG KONG--(BUSINESS WIRE)--#AntibodyDiscovery--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company's listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. The Company's IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen's market capitalization exceeds 25.9 billion RMB. Biocytogen's proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR mimic™) enable the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR mimic an...

BERLIN (dpa-AFX) - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and Merck KGaA (MKKGY, MRCG.DE, MRK.MI) announced that they have entered into an evaluation and option agreement to advance the de......